Primary immunodeficiencies are a group of disorders in which part of the body’s immune system is missing or does not function properly. The company is advancing the 20%
Under the deal, Eureka will apply its proprietary human sequence antibody libraries and its technology platform to discover antibodies recognizing intracellular proteins, which represent about 90% of cancer-specific
ImmunoClin will be responsible for managing and coordinating all aspects of the clinical trial on behalf of Celtic including protocol preparation, monitoring, project management, and regulatory reporting. Spotlight
The company said that this next Phase IIa dose expansion trial is a multicenter, randomized, open-label, controlled study, which is expected to be completed in the fourth quarter
VTU Technology currently offers a very broad and comprehensive Pichia pastoris expression platform and the deal grants Biomay access to VTU’s Pichia pastoris protein expression technology. Under the
Under the deal, CMS has secured exclusive assets and rights for the development and commercialisation of Faron’s lead drug candidate traumakine in China, Hong Kong, Macao and Taiwan
The company said that the updated breakthrough therapy designation reflects recently presented data on HCV genotype 1 patients with advanced cirrhosis (Child-Pugh Class B or C) and those
Currently, Revusiran is being evaluated in a Phase III trial to treat Familial Amyloidotic Cardiomyopathy (FAC), one of the predominant clinical manifestations of ATTR amyloidosis. Patient enrollment is
In Japan, Lenvima is the first molecular targeted treatment approved with an indication for unresectable thyroid cancer which covers differentiated thyroid cancer as well as medullary thyroid carcinoma
Under the deal, the OCTC will provide integrated research, clinical trial and core lab services, while Bryla will provide commercialization services in chemistry, manufacturing and control (CMC). Bryla
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.